ACM
KYNB

ADAR1 Capital Management’s Kyntra Bio KYNB Stock Holding History

ADAR1 Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,469
Closed -$71K – 304
2026
Q1 		$71K Hold
10,469
– – ﹤0.01% 293
2025
Q4 		$91.9K Buy
+10,469
New +$102K 0.01% 253
2024
Q4 		– Sell
-4,827
Closed -$48.2K – 248
2024
Q3 		$48.2K Buy
+4,827
New +$72.8K 0.01% 218
2024
Q2 		– Sell
-854
Closed -$50.2K – 285
2024
Q1 		$50.2K Buy
+854
New +$36.8K 0.01% 178

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

ADAR1 Capital Management's KYNB Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Kyntra Bio (KYNB) in Q2 2026, closing a stake of 10,469 shares — an estimated $71K sold.

ADAR1 Capital Management first reported a position in KYNB in Q1 2024 and held it in 4 quarters. The position peaked at $91.9K in Q4 2025. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Kyntra Bio position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 10,469 Kyntra Bio shares in Q2 2026, an estimated $71K.
  • ADAR1 Capital Management first reported a position in Kyntra Bio in Q1 2024 and held it in 4 quarters.
  • ADAR1 Capital Management's Kyntra Bio position peaked at $91.9K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.